The first dual GIP/GLP-1 receptor agonist, NNC0090-2746 (also known as RG7697, RO6811135, or MAR709), is a 40-amino acid peptide acylated with a C16:0 fatty acid to lysine residue at position 40 [ Figure 2 , Table 1 ]
doi: 10.1172/jci.insight.143385 23 YuSDoychevaDMGamdzykMYangYLenahanCLiGet al
Ankura is not a law firm and cannot provide legal advice.
If indicated, screening for eating disorders is advised, using a validated instrument suited for use in people with type 1 diabetes, for example, the Diabetes Eating Problems Survey-Revised (DEPS-R) or Eating Disorders Inventory-3 Risk Composite (EDI-3RC) [197]
As mentioned, semaglutide was originally developed to help people with type 2 diabetes manage their blood sugar levels
The blend simply makes that experiment cheaper to set up